<DOC>
	<DOC>NCT00325468</DOC>
	<brief_summary>An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women with Low Bone Mineral Density</brief_summary>
	<brief_title>An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density</brief_title>
	<detailed_description />
	<mesh_term>Denosumab</mesh_term>
	<criteria>Subject must be ambulatory Subject must have atteneded the 20010223 endofstudy visit and have completed all tests and procedures during the endofstudy visit signed informed consent must be obtained before any studyspecific procedures Experienced severe and/or serious adverse event which were thought to be related to denosumab administration during the 20010223 study. Developed grade 3 or 4 laboratory abnormalities based on Common Terminology Criteria for Adverse Events v3.0 during the 20010223 study which did not normalized upon follow up or did not have diagnosis or treatment. Newly diagnosed conditions such as hyper/hypo thyroidism, rheumatoid arthritis, other bone diseases, renal disease. Using therapies while participating in the 20010223 study such as oral bisphosphonates, calcitonin, oral strontium, SERMS, systemic glucocortiocosteriods.</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>bone loss</keyword>
	<keyword>osteoporosis</keyword>
</DOC>